US 2007/0184113 A1 · Pharmaceutical composition and process

Abstract

There is provided a formulation comprising N-(2-chloro-6-methylbenzoyl)4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2(diethylamino)ethyl ester and poloxamer 188 which is manufactured by a hot melt process.

Claims8

Dependent claims

A composition in a unit dosage form comprising

a) from about 50 mg to 400 mg of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethylester hydrochloride and on a % by weight basis b) from about 5 to 40% of poloxamer 188, c) from about 0 to 20% ProSolv SMCC50® and d) from about 0% to 60% of Lactose Anhydrous.

Dependencies are inferred from the claim text.

Facts

Application

11/652,349Filed 11 Jan 2007

Priority

18 Jan 2006

Published

9 Aug 2007

Term ends

Not estimatedThe source records don’t support an estimate.

Classification26 codes

A61K 9/4866
Filling excipients; Inactive ingredients: organic macromolecular compounds
A61K 9/1617
Excipients; Inactive ingredients: organic compounds, e.g. phospholipids, fats
A61K 9/1623
Organic compounds, e.g. phospholipids, fats: sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
A61K 9/1635
Organic macromolecular compounds: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, polyacrylates

Pharmaceutical composition and process

Life of this patent

Abstract

Claims8

Pharmaceutical composition and process

Life of this patent

Abstract

Claims8